Wells Fargo Upgrades GLUE, Jefferies Downgrades GBIO
Wells Fargo upgrades Monte Rosa Therapeutics on 2026 catalysts, while Jefferies downgrades Generation Bio due to its pending acquisition by Xoma.
/ 907 items
#Healthcare↓
Aldeyra's Dry Eye Treatment Gets FDA Review Extension
Aldeyra Therapeutics (ALDX) receives FDA extension for reproxalap dry eye drug review. New decision date set for March 2026 as agency requests additional trial documentation.
ReNu Knee Treatment Moves Forward with FDA Approval Process
Organogenesis receives FDA clearance to file for approval of ReNu, a regenerative treatment for knee osteoarthritis pain affecting millions of Americans.
Vanda Submits Application for New GPP Treatment
Vanda Pharmaceuticals files FDA application for imsidolimab, a promising new treatment for generalized pustular psoriasis, with potential approval by mid-2026.
Amphastar Wins FDA Approval for Affordable Osteoporosis Treatment
Amphastar Pharmaceuticals receives FDA approval for generic teriparatide injection, offering an affordable alternative to Eli Lilly's FORTEO for osteoporosis patients.
Jefferies Gives Buy Rating to Sera Prognostics with $5 Price Target
Jefferies starts coverage of Sera Prognostics with a Buy rating, highlighting its PreTRM test for predicting preterm birth and $1.6B U.S. market potential.